Fesarius Therapeutics

FesariusTherapeutics is a cutting-edge NY-based biotech start-up founded in 2015 with a mission to revolutionize the world of regenerative medicine. Their slogan, "A cutting-edge NY-based biotech start-up on a mission to revolutionize the world of regenerative medicine," reflects their dedication to innovation. The company focuses on developing innovative tissue-engineered products to transform reconstructive and aesthetic surgery. FesariusTherapeutics' flagship product, DermiSphere, is a revolutionary dermal regeneration template (DRT) for the management of wounds, based on technology spun-out from The Laboratory for Bioregenerative Medicine and Surgery at Weill Cornell Medicine. Their recent last investment of $800.00K Grant came from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) on 16th August 2023. This NY-based start-up operates within the Biotechnology and Manufacturing industries, solidifying its position as a pioneer in the field of regenerative medicine. With a focus on innovative technology and strong financial backing, FesariusTherapeutics is poised for significant growth and impact in the biotech space.